Agios Pharmaceuticals | AGIO - Current Assets


Agios Pharmaceuticals reported $717.67M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Astellas Pharma JPY 1.42T 19.35B Mar/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bayer EUR 35.3B 2.39B Mar/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Eli Lilly USD 54.84B 794M Mar/2026
Exelixis USD 1.21B 234.65M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novartis USD 27.35B 744M Jun/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 41.36B 1.46B Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026